BNTX vs. INSM: BioNTech vs. Insmed Stock Comparison
How do BioNTech (BNTX) and Insmed (INSM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioNTech (BNTX) and Insmed (INSM) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Insmed (INSM) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | BNTX | INSM |
|---|---|---|
| Name | BioNTech SE American Depositary Share | Insmed Incorporated |
| Country/Region | Germany | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 21.70 billion USD | 25.10 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | October 10, 2019 | June 1, 2000 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BNTX | INSM |
|---|---|---|
| Total Return (1Y) | -14.78% | -39.17% |
| Total Return (3Y, Annualized) | -3.99% | 70.17% |
| Total Return (5Y, Annualized) | -17.02% | 28.96% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BNTX | INSM |
|---|---|---|
| Volatility (1Y, Annualized) | 47.44% | 63.09% |
| Beta (5Y) | 1.30 | 0.80 |
| Max Drawdown (5Y) | -78.10% | -56.54% |
| Avg. Volume (3M) | 1.21M | 2.76M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BNTX | INSM |
|---|---|---|
| Sharpe Ratio (1Y) | -0.40 | -0.69 |
| Sortino Ratio (1Y) | -0.59 | -1.04 |
Profitability
ROE (TTM)
Both BioNTech (BNTX) at -8.14% and Insmed (INSM) at -72.45% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.14%
- Max
- 109.18%
- Q3
- 6.23%
- BNTX
- -8.14%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-72.45%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- INSM
- -72.45%
- Min
- -167.77%
Net Margin (TTM)
Both BioNTech (BNTX) at -60.87% and Insmed (INSM) at -39.85% report negative net margin values, usually indicating net losses over the period.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-60.87%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BNTX
- -60.87%
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- INSM
- -39.85%
Operating Margin (TTM)
Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BioNTech (BNTX) reports 30.28%, ranking against industry peers normally.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.28%
- Max
- 83.12%
- BNTX
- 30.28%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-15.60%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- INSM
- -15.60%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BNTX | INSM |
|---|---|---|
| ROE (TTM) | -8.14% | -72.45% |
| ROA (TTM) | -4.04% | -17.25% |
| Net Margin (TTM) | -60.87% | -39.85% |
| Operating Margin (TTM) | 30.28% | -15.60% |
| Gross Margin (TTM) | 76.73% | 84.40% |
Growth
Revenue Growth
Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while BioNTech (BNTX) at 4.32% is closer to the peer norm — faster top-line expansion for INSM.
EPS Growth
Neither BioNTech (BNTX) nor Insmed (INSM) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | BNTX | INSM |
|---|---|---|
| Revenue Growth (YoY) | 4.32% | 66.73% |
| Revenue Growth (3Y CAGR) | -45.06% | 35.20% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both BioNTech (BNTX) at 8.55 and Insmed (INSM) at 2.86 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.55
- Max
- 25.13
- Q3
- 12.13
- BNTX
- 8.55
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INSM
- 2.86
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
BioNTech (BNTX) at 0.02 keeps leverage in the lower quartile, while Insmed (INSM) at 1.01 sits in the higher-leverage quartile.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- BNTX
- 0.02
- Min
- 0.00
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01
- Max
- 1.42
- INSM
- 1.01
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BNTX | INSM |
|---|---|---|
| Current Ratio (MRQ) | 8.55 | 2.86 |
| Debt / Equity (MRQ) | 0.02 | 1.01 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither BioNTech (BNTX) nor Insmed (INSM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BNTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INSM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BioNTech (BNTX) nor Insmed (INSM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BNTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INSM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BNTX | INSM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BioNTech (BNTX) nor Insmed (INSM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BNTX
- --
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- INSM
- --
P/S Ratio (TTM)
On P/S ratio, both BioNTech (BNTX) at 8.96 and Insmed (INSM) at 16.52 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.96
- Max
- 58.18
- Q3
- 25.77
- BNTX
- 8.96
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.52
- Max
- 58.18
- Q3
- 25.77
- INSM
- 16.52
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile relative to book while Insmed (INSM) at 34.55 prices above its industry range — a wide valuation gap against assets.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.09
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BNTX
- 1.09
- Min
- -5.59
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.55
- INSM
- 34.55
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BNTX | INSM |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 8.96 | 16.52 |
| P/B Ratio (MRQ) | 1.09 | 34.55 |
| Free Cash Flow Yield (TTM) | -7.34% | -1.82% |